Please assess the completion status of the following clinical trial:

Trial Title: Long Term Safety of Vedolizumab (MLN0002) in Patients With Ulcerative Colitis and Crohn's Disease

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Confirmed and active ulcerative colitis (UC) or Crohn's Disease (CD)~  * Crohn's Disease Activity Index (CDAI) Score of 220 - 450 for participants with CD~ * Partial Mayo score of 2 - 7 for participants with UC~* Patient should be appropriate candidate for biologic therapy per guidelines~* Up-to-date on cancer screening~* No severe systemic disease~* Patients with evidence of abscess~* Agree to comply with study procedures including contraception~Exclusion Criteria:~* Low lymphocyte counts~* History of imaging abnormalities, multiple sclerosis (MS), brain tumor or other neurological illness~* Active or recent serious infections~* Recent treatment with biologic (i.e., Remicade) or investigational drug~* Impending surgery~* Any participants with vedolizumab human anti-human antibody (HAHA) titers ≥1:125 or with a previous immediate hypersensitivity reaction during or shortly after vedolizumab infusion

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Vedolizumab 2 mg/kg (Type: EXPERIMENTAL): Participants received vedolizumab, 2 mg/kg, intravenously (IV), on Days 1, 15 and 43, and thereafter once every 8 weeks for up to 78 weeks.
- Vedolizumab 6 mg/kg (Type: EXPERIMENTAL): Participants received vedolizumab, 6 mg/kg, IV, on Days 1, 15 and 43, and thereafter once every 8 weeks for up to 78 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).